Drugs / transferrin-CRM107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00052624 | Jul 2002 → ? | central nervous system neoplasm | Xenova Biomedix | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | transferrin-CRM107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00052624 ↗ |
| Known as | Tf-CRM107 | “All patients undergo stereotactic radiosurgery for tumor biopsy and placement of 2 intratumoral silastic infusion catheters pre-loaded with transferrin-CRM107 (Tf-CRM107).” NCT00052624 ↗ |
| Route | Other | “Patients receive intratumoral Tf-CRM107 over 3-7 days via catheter.” NCT00052624 ↗ |